Beyond Genetics: The Epigenetic Power of Bioregulator Peptides

The Alchemical Dream

Molecular nanotechnology has long been relegated to the realm of science fiction—depicted in novels like Escape from Furnace, where underground government experiments transform ordinary men into superhuman soldiers with blood capable of regenerating from almost any injury. These narratives echo the timeless human fascination with enhancement and healing, reminiscent of ancient alchemy's promise to transmute base metals into gold or concoct elixirs of immortality. In fantasy worlds like The Witcher series, potions and mutagens bestow supernatural abilities, accelerate healing, and push human capacity beyond natural limits.

It sounds like magic. It sounds like myth.

But what if something not too far removed from this already exists—not in the pages of science fiction, but hiding in plain sight within the scientific literature of a nation that, until recently, kept its greatest discoveries behind an iron curtain?

Drexler's Vision, Realized in Secret

When Eric Drexler published Engines of Creation: The Coming Era of Nanotechnology in 1986, he envisioned a future where molecular machines would revolutionize human existence—repairing cells from within, reversing aging, curing disease, and fundamentally rewriting the rules of biology. His vision captured imaginations worldwide, inspiring a generation of nanotechnology researchers.

Unknown to Drexler—and to most of the Western scientific establishment—that future wasn't distant at all. It already existed. A real-world application of biological nanotechnology was already changing lives, developed not in the gleaming laboratories of MIT or Stanford, but in the secretive research facilities of the Soviet Union during the height of the Cold War.

This technology would come to be called bioregulator peptides—and their story is one of military necessity, scientific ambition, isolation from Western science, and claims that, if they hold up, would challenge how we think about aging.

---

To understand how bioregulator peptides function requires examining the fundamental architecture of cellular control—the relationship between DNA, gene expression, and the epigenetic switches that determine which genetic programs are active or dormant.

DNA, Chromatin, and the Aging Process

Inside every cell in our bodies resides DNA—the master code that controls every biological process through the activation and silencing of genes. But DNA doesn't exist as a free-floating molecule. It's wrapped around protein scaffolds called histones, forming complex structures called chromatin, which are then packaged into the cell nucleus.

This packaging isn't merely structural—it's regulatory. The way DNA is wrapped, compressed, and organized directly determines which genes can be read (expressed) and which are effectively silenced.

Methylation: The Biological Clock

What activates or deactivates specific genes? Two primary factors control this process:

DNA Methylation is the addition of methyl groups (CH₃) to specific sites in the DNA sequence, particularly at CpG sites (regions where a cytosine nucleotide occurs next to a guanine nucleotide). These methylation patterns correlate directly with the aging process.

As we age, certain CpG sites undergo progressive methylation changes that reduce the functional activity of genes essential for maintaining youthful cellular function. Other sites undergo demethylation, activating genes that should remain silent. This epigenetic drift—the gradual shift in methylation patterns away from the youthful baseline—represents one of the most fundamental hallmarks of biological aging.

The Horvath clock, developed by UCLA biostatistician Steve Horvath, uses methylation patterns at specific CpG sites to calculate biological age with remarkable precision. This epigenetic age often diverges significantly from chronological age—athletes under extreme training stress may have biological ages 5-10 years older than their calendar age, while individuals with exceptional longevity often show biological ages years younger than their chronological years.

Histones: The Gatekeepers of Gene Expression

The second critical factor controlling gene expression is the structure and modification of histone proteins—the spools around which DNA is wrapped.

Histones can exist in different states of modification (acetylation, methylation, phosphorylation), and these modifications determine how tightly DNA is wound. The tighter the wrapping, the less accessible the genes become.

Heterochromatin is a tightly packed, condensed form of chromatin that effectively silences genes. As we age, heterochromatin becomes increasingly prevalent—more and more of our genome gets locked away in this transcriptionally inactive state. Genes that were readily accessible and highly expressed in youth become progressively silenced.

Euchromatin is a loosely packed, accessible form of chromatin that allows genes to be actively transcribed. Maintaining euchromatin structure is essential for cellular vitality, regenerative capacity, and metabolic function.

The progressive shift from euchromatin to heterochromatin during aging—termed heterochromatinization—represents one of the primary mechanisms through which cells lose function, fail to regenerate, and accumulate damage.

The Peptide Intervention: A Dual Mechanism

Bioregulator peptides operate through a sophisticated dual mechanism that directly addresses both methylation and chromatin structure:

Mechanism 1: Chromatin Remodeling

In the model Khavinson's group proposed, a short peptide enters the cell directly because of its small size, without receptor-mediated uptake, and binds specific histone proteins. The precise type of histone targeted depends on the peptide's amino acid sequence.

This binding is proposed to loosen chromatin, a process called de-heterochromatinization—essentially unwrapping tightly packed genetic material. In this model, the process would:

• Enhances the expression of genes that are losing their activity due to aging
• Reactivates genes that have been completely silenced by heterochromatinization
• Restores more youthful chromatin architecture
• Has a positive effect on overall cellular function

Russian research laboratories have produced 3D molecular models (viewed with special glasses) showing these peptides interlocking with DNA double helixes "like a key going into a lock"—a precise molecular fit that enables targeted gene regulation.

Mechanism 2: Direct Gene Regulation

Beyond chromatin modification, bioregulator peptides can bind directly to DNA sequences in promoter regions—genetic switches that control whether genes are turned on or off.

This direct DNA binding allows dynamic regulation: the same peptide can up-regulate gene expression when function is insufficient, or down-regulate it when activity is excessive. The direction of regulation depends on the current state of the body and its physiological needs—a property that makes bioregulators fundamentally different from drugs, which typically push function in one direction regardless of baseline status.

Duration and Proposed Effects on Biological Age

A common question: How long do these peptides last? What's their half-life?

Khavinson's group argued that the effect outlasts the molecule: short peptides are broken down quickly, but the gene-expression changes they are proposed to trigger by binding histones and DNA may persist after the peptide itself is gone.

When peptidase enzymes eventually cleave the peptide bonds, breaking the peptide into individual amino acids, those amino acids are recycled by the cell for other metabolic processes. In this model, the gene-expression changes started while the peptide was bound continue for weeks to months, depending on the peptide and tissue.

This is the rationale for giving bioregulators in short courses (typically 10-20 days in the Russian protocols), with effects said to last for months. The peptide is pictured as a molecular switch that stays flipped after it is removed. Pharmacokinetic studies to confirm this are lacking.

The Horvath Clock: Measuring What Matters

We have two types of age:

Chronological age is our actual age—the number of years we've been alive.

Biological age is the age of our DNA and cellular systems—determined by methylation patterns, telomere length, cellular senescence markers, and functional capacity.

The Horvath clock, currently the most accurate method for measuring biological age, analyzes methylation patterns at hundreds of specific CpG sites across the genome. These sites are regulatory regions involved in gene expression, and their methylation status is a strong statistical predictor of functional age and remaining lifespan across populations.

Proponents report that people following bioregulator protocols for months to two years have shown lower epigenetic-clock readings, with figures of 3-7 years often quoted. We could not find a peer-reviewed, controlled study that shows this; the numbers come mainly from practitioner reports and unpublished data.

Epigenetic clocks also vary between tests and labs, so single before-and-after readings should be read with caution.

---

Historical Foundation: From Pavlov to Peptides

The Saint Petersburg Institute of Bioregulation and Gerontology had a distinguished scientific lineage. Ivan Pavlov, the Nobel Prize-winning physiologist (1904, Physiology of Digestion), conducted his pioneering work on digestive processes at related institutions in Saint Petersburg.

Pavlov's research on dogs revealed that the digestive system secretes specific substances in response to food intake—substances we now recognize as peptides. One gastric peptide later studied in the West, BPC (Body Protection Compound), belongs to a separate line of research from Croatian, not Russian, laboratories; its synthetic fragment BPC-157 has been studied mostly in animals.

Khavinson's group later developed bioregulators aimed at the digestive tract:

• Stamakort: a natural stomach peptide complex (GARMONIA A-10), sold today as a dietary supplement for digestive support
• Chonluten: a synthetic tripeptide (Glu-Asp-Gly) studied mainly for the lungs, which the same group also examined in the stomach lining

Soviet and Russian researchers reported studies of these peptides on the gastric lining. The reports were small, came from the developers, and have not been replicated independently, so they say little about any supplement sold today.

For a stomach-tissue bioregulator, Vita-Stream sells Stamakort alongside two products from its own Vita Peptides line: Stomek (stomach) and Gastrogen (gastric mucin). All three are structure/function supplements; none has been tested in a human trial.

Extraction and Purification

Khavinson's team developed a sophisticated extraction methodology using organs from cattle younger than one year old. Several critical factors governed this process:

Source Material: According to the developers, only Russian cattle were used, from herds with no documented history of prion disease (including BSE) or infectious agents. Sourcing for products sold outside Russia today varies by manufacturer; check each label.

Extraction Process: The developers state that purification follows pharmacopoeia requirements. Multiple filtration, centrifugation, and chromatographic steps isolate peptides from other tissue components.

Molecular Weight: All bioregulator peptides maintain molecular weights below 5,000 daltons (with cortexin being the exception at under 10,000 daltons). This is significantly smaller than prions, which typically exceed 30,000 daltons—an important safety distinction.

Natural Matrix Advantage: Natural extracts contain not only the target peptide but also up to 21 free-floating trace amino acids—a biological matrix that's absent in purely synthetic versions. Khavinson held that natural extracts act longer and need less frequent dosing than synthetic peptides, and attributed this to the amino acid matrix; this has not been tested head-to-head.

The Three-Tier Classification System

Khavinson developed three distinct categories of bioregulator peptides, each with specific applications and pharmacological properties:

1. Cytomaxes

Injectable polypeptide complexes used in Russian clinics and hospitals under physician supervision.

According to Khavinson, cytomaxes have a slower onset but longer-lasting effects, which is why they were given in longer courses. He attributed this to their larger molecules and complex composition.

2. Cytamins

Functionally equivalent to cytomaxes but formulated for oral administration and supplemented with cofactors, vitamins, and minerals that enhance bioavailability and support peptide activity.

Both are organ-specific tissue extracts: thymus peptides were developed with the immune system in mind, retinal peptides with the eye, vascular peptides with the blood vessels, and so on.

Oral versions are sold over the counter in Russia as dietary supplements. Naming has drifted since: the GARMONIA "Cytomax" capsules sold online today, such as Vladonix or Visoluten, are oral natural-peptide supplements, not injectables.

Here is how those organ categories map to capsules Vita-Stream sells today. Where Vita-Stream's own Vita Peptides line covers the tissue, we list it first. These are structure/function supplements; none has been tested in a human trial, and none is the same product as the Russian injectables discussed elsewhere in this article.

3. Cytogens

Pure short-chain peptides identified through spectrometric analysis of cytomaxes. These must be di-, tri-, or tetrapeptides (2-4 amino acids in length):

• Dipeptides: Vilon (Lys-Glu), studied for its role in immune regulation. Vilon itself is not sold by Vita-Stream; the closest thymus option is Thymusol.
• Tripeptides: Pinealon (Glu-Asp-Arg), studied for brain function; Chonluten (Glu-Asp-Gly) for lung function; Vesugen (Lys-Glu-Asp) for vascular function
• Tetrapeptides: Epitalon (Ala-Glu-Asp-Gly), studied for its role in pineal function and aging; Bronchogen (Ala-Glu-Asp-Lys) for respiratory function

Khavinson recommended cytogens when a faster effect was wanted, arguing that their small size allows:

• Easier absorption (an oral bioavailability figure of ~90% is often quoted, but we found no published pharmacokinetic data to support it)
• Rapid entry into cells
• Quick binding to histones and DNA, in his model
• Faster onset (days rather than weeks, by his account)

Epitalon itself is not sold by Vita-Stream; our Epitalon page covers the research and what is sold instead. The natural pineal-extract capsule Vita-Stream sells is Endoluten (GARMONIA A-8), and Pinealon is sold as PINEAL0N in the Cytogen line. The Vita Peptides house line has no pineal or brain product.

Clinical Strategy

The standard clinical approach involves:

1. Start with cytogens: when a faster effect is wanted, one or more cytogens aimed at the organ systems of interest
2. Move to cytomaxes/cytamins: longer-acting polypeptide formulations for continued use
3. Combinations: Russian protocols describe using up to six different peptides at once, each aimed at a different organ system. Combination use has not been studied in controlled trials.

---

Bidirectional Normalization

The term "bioregulator" reflects Khavinson's central claim: that these peptides normalize function in both directions rather than simply raising or lowering activity the way most drugs do.

Proponents see this as the key difference from conventional drugs; it remains a hypothesis.

The Thyroid Example

Khavinson often used the thyroid to explain the idea. In his model, a thyroid peptide does not simply push hormone output up or down. Instead, it is said to nudge thyroid-cell activity back toward its normal range from either direction.

The peptide, in this account, does not "know" which way to go; it responds to the cell's own feedback signals. Khavinson's group described the same pattern for the pancreas, adrenals and gonads.

This two-way effect is a hypothesis drawn from cell and animal work by the originating group. It has not been shown in controlled human trials, and it is not a reason to change or stop any medication.

For a thyroid-tissue bioregulator, Vita-Stream's house line includes Thyrix (natural thyroid peptides), and it also sells Thyreogen (GARMONIA A-2). Both are dietary supplements for normal thyroid and metabolic balance. Talk to your clinician first if you take thyroid medication or have a thyroid condition.

Universal 30% Cellular Reserve

Khavinson's most provocative hypothesis: Every cell maintains approximately 30-42% functional reserve capacity—dormant genetic programs that can be reactivated under appropriate stimulation.

Evidence supporting this theory:

Lifespan: Maximum human lifespan (~120 years) exceeds average lifespan (~80 years) by approximately 30-40%. The centenarians and supercentenarians who reach maximum lifespan aren't accessing "special" genes—they're simply maintaining fuller expression of the standard genetic program that ages more slowly in most people.

Athletic Performance: Russian reports on elite athletes describe performance gains of around 30-35% in some metrics (endurance, strength, power output, recovery rate).

Agricultural Applications: The Tel Aviv strawberry study (discussed below) reportedly found 20-30% yield increases with peptide treatment.

Organ Reserve: Physiological studies have long recognized organ reserve capacity—we can survive with one kidney (50% reduction), partial liver resection (the liver can lose 70% of its mass and regenerate), partial lung removal, etc. This reserve exists at the cellular level as well.

Evidence Across Kingdoms

Khavinson read the recurrence of a roughly 30% figure across species and applications as a sign of a general principle. Critics note that the figures come from very different measures, so the match may be coincidence.

In his view, evolution equipped cells with spare capacity as a buffer against stress, injury and aging, so that we normally run at about 70% of a theoretical maximum, and bioregulator peptides could tap into the remaining reserve. This has not been tested directly.

---

Safety Profile: The "100 Million Doses" Claim

Professor Khavinson has estimated that over 100 million doses of bioregulator peptides have been administered across 40+ years of use in Russia and Russian-speaking nations (Ukraine, Kazakhstan, Georgia, Belarus).

If accurate, that is a long record of use, but it is an estimate, not a tracked figure.

Adverse events: Russian sources report few serious side effects. But there is no systematic safety monitoring of these products outside Russia, and an absence of reports is not proof of safety. Labels for today's oral products list pregnancy, breastfeeding and individual intolerance as contraindications. Proponents point out that reported use has included:

• Multiple peptides used simultaneously
• Long-term continuous use (some patients have used bioregulators for 20+ years)
• Diverse patient populations (elderly, athletes, children, chronically ill)
• Various administration routes (injectable, oral, sublingual)

Proponents attribute the low reported toxicity to the proposed mechanism—normalizing function rather than forcing supraphysiological states. That comparison with hormone therapy has not been tested.

Current Regulatory Status:

• 21 bioregulator formulations available over-the-counter in Russia as food supplements
• Injectable forms require prescription but are widely used in clinical practice
• Some injectable preparations (such as Thymalin, Retinalamin and Cortexin) are registered medicines in Russia
• No approval or recognition in FDA/EMA regulatory frameworks (yet)

Dr. Bill Lawrence's American Experience

Dr. Bill Lawrence, an American physician with conventional medical training, is one of the few Western doctors who has described using bioregulators in practice.

Practice Integration:

• Nearly five years of clinical experience (as of 2025)
• Over 150 patients treated with various bioregulator combinations
• Before-and-after biomarker testing, which he discusses in interviews and talks

Areas he has discussed: metabolic health, cardiovascular health, immune function, age-related decline in muscle, cognition and vision, and athletic performance.

Epigenetic-age readings: Lawrence has reported an average drop of 4.67 years on DNA-methylation (Horvath) clocks among patients following bioregulator protocols for months to two years. These are his clinic's own figures, not a published controlled study, and patients often changed diet, exercise and other habits at the same time.

He has also described individual cases, such as a 65-year-old whose clock reading fell from 72 to 61. Single cases cannot separate the peptides from other changes or from test-to-test variation.

Biomarker Validation

Horvath Clock: DNA methylation patterns at specific CpG sites provide the most accurate biological age measurement currently available. Unlike individual biomarkers that may show conflicting age estimates, the Horvath clock integrates genome-wide methylation status into a single biological age metric that correlates strongly with:

• Mortality risk
• Disease incidence
• Functional decline
• Remaining lifespan

Proponents say Horvath-clock results back up the improvements patients describe (more energy, better sleep, sharper thinking, better physical function). Published, controlled data to support this are still missing.

Telomere Length: Cell studies by Khavinson's group reported that Epitalon increased telomerase activity and telomere length in cultured human cells. Whether anything similar happens in people taking any product has not been shown.

Clinical Biomarkers: Practitioners also report changes in inflammatory, metabolic, hormonal, immune and cognitive measures. These reports are uncontrolled.

Comparative Advantages Over Hormone Therapy

Complexity Reduction: The human endocrine system comprises over 400 hormones with intricate feedback loops and cross-regulatory relationships. Hormone replacement therapy, while beneficial, requires sophisticated management to avoid cascade effects:

• DHEA supplementation can suppress endogenous cortisol production
• Testosterone can convert to estrogen via aromatase
• Thyroid hormone affects sex hormone binding globulin, altering free testosterone
• Growth hormone affects insulin sensitivity, thyroid function, and cortisol

Each intervention creates ripple effects requiring additional interventions to manage.

Endogenous Production: Proponents argue that bioregulators work with the body's own hormone production rather than replacing it, which in theory would avoid:

• Down-regulation of endocrine glands
• Loss of natural circadian rhythms
• Dependency on external hormone sources
• Supraphysiological peaks and non-physiological valleys

Organ Specificity: While hormones often exert widespread systemic effects (cortisol affects virtually every cell type), bioregulators demonstrate remarkable organ specificity:

• Thyroid peptide: the thyroid
• Retinal peptide: the retina
• Vascular peptide: blood vessel walls
• Pancreatic peptide: the pancreas

This organ specificity is claimed by the developers; it has not been demonstrated in human trials, and no trial has compared bioregulators with hormone therapy.

Personalized Combinations: Practitioners often combine 4-6 bioregulators, each aimed at a different organ system.

---

Western Clinical Trials

Despite decades of use in Russia, FDA approval for US marketing would require:

Phase I: Safety studies in healthy volunteers

• Pharmacokinetics (absorption, distribution, metabolism, excretion)
• Safety and tolerability at various doses
• Drug interaction studies

Phase II: Efficacy studies in target conditions

• Proof-of-concept in specific diseases
• Dose-ranging to establish optimal protocols
• Biomarker validation (Horvath clock, telomeres, inflammatory markers)

Phase III: Large-scale randomized controlled trials

• Hundreds to thousands of participants
• Comparison to standard of care or placebo
• Long-term safety monitoring
• Cost-effectiveness analysis

Phase IV: Post-marketing surveillance

• Real-world effectiveness
• Rare adverse events
• Long-term outcomes

IND Pathways: Several peptides could, in principle, be studied under Investigational New Drug applications, for example:

• Retinalamin for age-related macular degeneration
• Thymus peptide for immune senescence
• Pineal peptide for circadian rhythm disorders
• Vascular peptide for vascular aging
• Epitalon for longevity/healthspan extension

The challenge: many bioregulators are natural extracts or very short peptides that are hard to protect with new patents. The pharmaceutical industry has little financial incentive to fund the $500 million - $2 billion required for full FDA approval without patent protection enabling monopoly pricing.

Agricultural Development

The Tel Aviv strawberry research represents proof-of-concept; systematic studies across staple crops could transform global food security.

Crop-Specific Optimization:

• Wheat, rice, corn, soybeans (staple grains)
• Potatoes, cassava (staple tubers)
• Tomatoes, peppers, cucurbits (high-value vegetables)
• Apples, citrus, berries (fruit crops)

Each crop may respond optimally to different peptide formulations and application protocols.

Stress Resilience Testing: Evaluate bioregulators under:

• Drought stress (increasingly critical as climate changes)
• Salinity (affecting coastal and irrigated cropland)
• Temperature extremes (heat waves, cold snaps)
• Pest pressure (insects, pathogens)
• Nutrient deficiency (low-input agriculture)

If bioregulators maintain yield under stress conditions that would otherwise cause crop failure, this could be more valuable than yield increases under optimal conditions.

Organic Certification: Natural derivation and gene-activation mechanisms (rather than introducing foreign compounds) position bioregulators for organic agriculture markets.

Developing World Applications: Where access to fertilizers, pesticides, and irrigation is limited, peptide-enhanced crops could increase food production without infrastructure investments.

Mechanism Elucidation

Despite decades of clinical use, molecular details of bioregulator action remain incompletely understood.

Structural Biology:

• High-resolution crystallography of peptide-histone complexes
• NMR spectroscopy of peptide-DNA interactions
• Cryo-electron microscopy of chromatin remodeling

These techniques could reveal precise atomic-level mechanisms.

Epigenetic Mapping:

• Genome-wide methylation analysis before/after bioregulator treatment
• Histone modification profiling (acetylation, methylation, phosphorylation patterns)
• Chromatin accessibility assays (ATAC-seq, DNase-seq)
• RNA sequencing to identify activated gene programs

This would create bioregulator fingerprints—specific genetic programs activated by each peptide, enabling rational design of combination protocols.

Adaptogen Hypothesis: Traditional adaptogenic plants (Rhodiola, Ashwagandha, Panax ginseng, Schisandra, Maca) demonstrate homeostatic effects similar to bioregulators—raising what's low, lowering what's high.

Systematic analysis of these plants for bioregulator peptide content could:

• Explain their therapeutic mechanisms
• Enable isolation of additional bioactive peptides
• Validate traditional medicine practices with molecular evidence

Personalized Medicine Applications

Biomarker-Guided Therapy: Combining:

• Horvath clock biological age assessment
• Telomere length measurement
• Comprehensive metabolic panels
• Hormonal profiles
• Genetic predisposition analysis (SNP testing)

...could enable precision bioregulator prescribing tailored to individual aging patterns.

Predictive Modeling: With sufficient data, machine learning could predict which peptide combinations will be most effective for a given individual based on:

• Current biomarker profile
• Genetic background
• Health history
• Lifestyle factors
• Treatment goals

Combinations: Practitioners report using 4-6 bioregulators at once; whether combinations beat single products has never been tested. Systematic investigation could:

• Identify optimal combinations for specific conditions
• Establish dosing ratios between peptides
• Determine ideal treatment sequences
• Optimize administration routes and timing

Preventive Gerontology: Some researchers propose starting bioregulators earlier in life, guided by biomarkers. This idea has not been tested.

---

Bioregulator Peptides: Short-chain amino acid sequences (typically 2-4 amino acids) that modulate gene expression through epigenetic mechanisms, acting bidirectionally to normalize cellular function.

Chromatin: The complex of DNA and histone proteins that packages genetic material within the cell nucleus. Chromatin structure determines which genes can be expressed.

Heterochromatin: Tightly packed, condensed chromatin structure associated with gene silencing and transcriptional inactivity. Increases with aging.

Euchromatin: Loosely packed, accessible chromatin structure that permits active gene transcription. Decreases with aging.

De-heterochromatinization: The process of unwrapping condensed heterochromatin to restore gene accessibility and expression—a mechanism proposed for bioregulators.

CpG Sites: Regions of DNA where a cytosine nucleotide occurs next to a guanine nucleotide. Methylation patterns at these sites regulate gene expression and correlate with biological age.

Horvath Clock: An epigenetic age estimator that uses DNA methylation patterns at hundreds of specific CpG sites to calculate biological age independent of chronological age. The most accurate biological age measurement currently available.

Cytomaxes: Injectable polypeptide bioregulator complexes used in Russian clinical settings; organ-specific tissue extracts with slower onset but longer-lasting effects.

Cytamins: Oral bioregulator formulations equivalent to cytomaxes but supplemented with cofactors, vitamins, and minerals to enhance bioavailability.

Cytogens: Pure short-chain peptides (di-, tri-, or tetrapeptides) isolated from cytomaxes through spectrometric analysis; described by their developers as faster-acting because of their small size.

PPAR (Peroxisome Proliferator-Activated Receptors): Nuclear receptor proteins that regulate gene expression controlling glucose and lipid metabolism, particularly in muscle and adipose tissue.

Irisin: A hormone released from muscle tissue that regulates metabolism, particularly glucose uptake and fatty acid oxidation. Russian reports describe bioregulator effects on irisin.

Telomeres: Protective DNA-protein structures at chromosome ends that shorten with each cell division. Telomere length correlates with cellular age and remaining replicative capacity.

Epigenetics: The study of heritable changes in gene expression that don't involve alterations to the DNA sequence itself—primarily methylation and histone modifications.

Senescence: The state of permanent cell cycle arrest that accumulates with aging. Senescent cells remain metabolically active but cannot divide and secrete inflammatory factors.

Bioregulation: The bidirectional normalization of cellular function—raising what's too low, lowering what's too high, always trending toward homeostatic balance.

Reserve Capacity Theory: Khavinson's hypothesis that every cell maintains approximately 30-42% dormant genetic potential that can be reactivated through appropriate stimulation, which he used to explain ~30% improvements reported across species and applications.

---

This article retells the history of bioregulator peptides as described in Russian scientific literature, practitioner reports and secondary sources. Reported findings are attributed; most have not been independently confirmed. These statements have not been evaluated by the FDA. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease.